Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCO: Continuation vs Discontinuation of SGLT-2 Inhibitors Before Cardiac Surgery
2025-524395-30-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin and empagliflozin in heart failure (HF) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Composite postoperative cardiovascular outcome at 30 days. Planned start May 2026; status: authorised.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2025-524395-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524395-30-00.